CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon J. Harrison(Peter MacCallum Cancer Centre), Piers Blombery(The University of Melbourne), Brad Foulk(Janssen (United States)), Nikoletta Lendvai(Centro de Investigación del Cáncer), Junchen Gu(Janssen (United States)), Stephen Lade(The University of Texas MD Anderson Cancer Center), Tamia Nguyen(The University of Melbourne), Marzia Rahman(Peter MacCallum Cancer Centre), Sean M. Grimmond(Center for Genomic Science), Denis A. Smirnov(Eon Corporation (United States)), Katherine Li(Janssen (United States)), Erin Lee(Janssen (United States)), Shirin Jadidi(Janssen (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Loreta Marquez(Janssen (United States)), Nicole M. Haynes(The University of Melbourne), Carolina Lonardi(Janssen (Switzerland)), Ana Slaughter(Centro de Investigación del Cáncer), Jeremy Er(The Royal Melbourne Hospital), Tito Roccia(Janssen (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), Jessica Li(Sana Biotechnology (United States)), Hao Zhao(Janssen (United States)), Octavio Costa Filho(490 BioTech (United States)), Nitin Patel(Centro de Investigación del Cáncer), Dong Geng, Hannah G. Kelly(Peter MacCallum Cancer Centre)
Blood
November 2, 2023
10.1182/blood-2023-178806
Cited by 99

Related Papers

Whole genomes redefine the mutational landscape of pancreatic cancer
|Nature|2015|2.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
|Science|2007|852
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719